Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

Clin Transl Oncol. 2007 Feb;9(2):119-20. doi: 10.1007/s12094-007-0023-6.

Abstract

We report here a taxol-bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Bevacizumab
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Melanoma / drug therapy*
  • Paclitaxel / administration & dosage*
  • Remission Induction
  • Skin Neoplasms / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic
  • Bevacizumab
  • Paclitaxel